Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

There are many possible explanations for that, including side effects and the drug’s cost. According to a KFF analysis, the ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

Safety Concerns and Liability Issues for GLP-1 Drugs GLP-1 medications ... For instance, at the start of 2024, the US list prices of Ozempic (Novo Nordisk) and Mounjaro (Eli Lilly) increased ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

At the J.P. Morgan Health Care conference this week in San Francisco, drugmakers had their sights set on the next generation of GLP-1 medications, alternatives, and a growing list of indications ...

Medicare’s next drug price negotiations will treat Novo Nordisk ... are also already likely to be discounted from their list prices — $998 a month for Ozempic and Rybelsus, $1,349 a month ...